Medtronic’s Stealth AXiS Surgical System Gains FDA Approval for Cranial and ENT Procedures, Expanding Beyond Spine
Medtronic plc (NYSE: MDT) announced it has received U.S. Food and Drug Administration (FDA) marketing...
Jenscare Completes First-in-Human Study of iJensRobo Robot-Assisted Tricuspid Valve Replacement System
Jenscare Scientific Co., Ltd. (HKG: 9877), a pioneer in structural heart interventions, announced the successful...
Clover Biopharmaceuticals Completes Enrollment in Phase II Trial of Trimer-Tag Respiratory Combination Vaccines for Older Adults
Clover Biopharmaceuticals Ltd. (HKG: 2197) announced the completion of subject enrollment in a Phase II...
J&J’s Darzalex SC Becomes First Oncology Injectable in Europe Approved for Patient Self-Administration
Johnson & Johnson (J&J, NYSE: JNJ) announced that the Committee for Medicinal Products for Human...
Novartis to Acquire Excellergy for Up to $2 Billion, Adding Next-Gen Anti-IgE Antibody Exl-111 to Immunology Pipeline
Novartis AG (NYSE: NVS) announced an agreement to acquire Excellergy, Inc., a U.S.-based biotech, for...
GSK’s Bepirovirsen Receives EMA Review Acceptance for Chronic Hepatitis B, Pioneering Triple-Mechanism ASO Therapy
GlaxoSmithKline plc (GSK, NYSE: GSK) announced that the European Medicines Agency (EMA) has accepted for...
AstraZeneca’s Tozorakimab Reduces COPD Exacerbations in Phase III Trials, Targeting IL-33 in First-in-Class Approach
AstraZeneca plc (NYSE: AZN) announced positive top-line results from two pivotal Phase III trials—OBERON and...
J&J’s Icotyde Sustains and Improves Complete Skin Clearance in Psoriasis Through 52 Weeks, Outperforming Deucravacitinib on Safety
Johnson & Johnson (J&J, NYSE: JNJ) released 52-week long-term data from the Phase III ICONIC-ADVANCE...
Takeda’s Zasocitinib Demonstrates Superior Efficacy Over Apremilast and Placebo in Phase III Psoriasis Trials with Unprecedented TYK2 Selectivity
Takeda Pharmaceutical Company Limited (TYO: 4502, NYSE: TAK) reported positive top-line results from two pivotal...
Huahai Pharma and Almirall Strike $340M Monoclonal Antibody Licensing Deal Targeting Dermatology and Beyond
Zhejiang Huahai Pharmaceutical Co., Ltd. (SHA: 600521) announced a strategic licensing agreement with Almirall S.A....
Sinovac Biotech and Indonesia’s Bio Farma Forge Strategic Alliance to Expand Vaccine Access Across Developing Markets
Sinovac Biotech Ltd. (NASDAQ: SVA) announced the signing of a strategic cooperation memorandum with PT...
RemeGen Posts 89% Revenue Surge in 2025, Returns to Profitability on Strength of Tai’ai and Disitamab Vedotin
RemeGen Co., Ltd. (HKG: 9995, SHA: 688331) reported RMB 3.251 billion (USD 470 million) in...
Eli Lilly’s Taltz-Zepbound Combo Shows Superior Efficacy in Obese Psoriatic Arthritis Patients in Phase IIIb TOGETHER-PsA Trial
Eli Lilly and Company (NYSE: LLY) reported positive top-line results from the TOGETHER-PsA Phase IIIb...
Hansoh Pharma Reports 22.6% Revenue Growth in 2025, Driven by Oncology and $4.54B in Global Licensing Deals
Hansoh Pharmaceutical Group Co., Ltd. (HKG: 3692) announced robust 2025 financial results, with RMB 15.028...
Insilico Medicine Reports $56.2M Revenue in 2025 Amid Strategic Pipeline Buildout; Cash Reserves Stand at $393M
Insilico Medicine (HKG: 3696), a pioneer in generative AI-driven drug discovery, released its 2025 financial...
Eli Lilly’s Lebrikizumab Demonstrates Four-Year Sustained Efficacy in Atopic Dermatitis, Reinforcing IL-13 as Core Therapeutic Target
Eli Lilly and Company (NYSE: LLY) reported new long-term data from an open-label extension study...
BrainAurora Medical Partners with Tokyo Lifestyle to Launch AI-Powered Digital Health Platform for Elderly Cognitive Care Across Asia
BrainAurora Medical Technology Limited (HKG: 6681), China’s pioneer in neuroscience-AI integrated digital therapeutics, announced a...
UCB’s Bimzelx Wins NMPA Approval for Two New Indications – IL-17A/F Dual-Target Antibody Expands into Psoriasis and Hidradenitis Suppurativa
UCB (EBR: UCB) announced National Medical Products Administration (NMPA) approval for Bimzelx (bimekizumab) in two...
Enhertu Wins China Approval for HER2+ Early Breast Cancer – ADC Sequential Therapy Shows 67% pCR Rate in Phase III DESTINY-Breast11
Enhertu (trastuzumab deruxtecan), the HER2-targeted antibody-drug conjugate (ADC) co-developed by AstraZeneca (NYSE: AZN) and Daiichi...
FDA Approves Rocket Pharma’s Kresladi – First Gene Therapy for Severe Leukocyte Adhesion Deficiency Type I
The U.S. Food and Drug Administration (FDA) this week approved Rocket Pharmaceuticals’ Kresladi (marnetegragene autotemcel),...